Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology t
Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein.
대표청구항▼
1. A method for treating a cancer, comprising administering to a subject with the cancer a therapeutically effective amount of a pharmaceutical product comprising: (a) a first therapeutic agent comprising an inhibitor of an interaction between p53 and MDM2 and/or an inhibitor of an interaction betwe
1. A method for treating a cancer, comprising administering to a subject with the cancer a therapeutically effective amount of a pharmaceutical product comprising: (a) a first therapeutic agent comprising an inhibitor of an interaction between p53 and MDM2 and/or an inhibitor of an interaction between p53 and MDMX, and(b) a second therapeutic agent comprising a chemotherapeutic agent;wherein the first therapeutic agent is a peptidomimetic macrocycle comprising an amino acid sequence with at least about 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ IP NOs: 10-457, or pharmaceutically acceptable salt thereof; and wherein the peptidomimetic macrocycle has a Formula: wherein: each of Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, and Xaa10 is independently an amino acid, wherein at least three of Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, and Xaa10 are the same amino acids as the amino acid at the corresponding position of the sequence Phe3-X4-His5- Tyr6-Trp7-Ala8-Gln9-Leu10-X11-Ser12 (SEQ ID NO: 8) or Phe3-X4-Glu5-Tyr6-Trp7-Ala8-Gln9-Leu10/Cba10-X11-Ala12 (SEQ ID NO: 9), wherein each X4 and X11 is independently an amino acid:each D is independently an amino acid;each E is independently an amino acid selected from the group consisting of Ala (alanine), D-Ala (D-alanine), Aib (α-aminoisobutyric acid), Sar (N-methyl glycine), and Ser (serine);R1 and R2 are independently -H, alkyl, alkenyl, alkyenyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or forms a macrocycle-forming linker L′ connected to the alpha position of one of said D or E amino acids;L and L′ are independently a macrocycle-forminig linker;each R5 is independently halogen, alkyl. -OR6, -N(R6)2, -SR6, -SOR6, SO2R6, -CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent;each R6is independently -H, alkyl, alkenyl, alkenyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;R7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R5, or part of a cyclic structure with a D residue;R8 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R5, or part of a cyclic structure with an E residue;v is an integer from 1-10;w is an integer from 3-10; andand wherein the cancer is head and neck cancer, melanoma, lung cancer, breast cancer, glioma, or a hematological cancer. 2. The method of claim 1, wherein the first therapeutic agent and the second therapeutic agent are administered separately or as a single composition. 3. The method of claim 1, wherein the first therapeutic agent, the second therapeutic agent, or both are administered intravenously, intraperitoneally or subcutaneously. 4. The method of claim 1, wherein the second therapeutic agent is administered at a dosage of between 1% to 100% of a dosage of the second therapeutic agent normally administered in a monotherapy regimen. 5. The method of claim 1, wherein the cancer is selected from the group consisting of head and neck cancer, melanoma, lung cancer, breast cancer, and glioma. 6. The method of claim 1, wherein the cancer is a hematological cancer. 7. The method of claim 6, wherein the hematological cancer is acute myelogenous leukemia (AML). 8. The method of claim 1, wherein the second therapeutic agent is selected from the group consisting of a small molecule, a polypeptide, and an oligonucleotide. 9. The method of claim 1, wherein L and L′ are independently a macrocycle-forming linker of the formula -L1-L2-, wherein: L1 and L2 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [-R4-K-R4-]n, each being optionally substituted with R5;each R4 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, or heterocycloalkylene;each K is independently O, SO, SO2, CO, CO2, or CONR3; and each n is independently an integer from 1-5. 10. The method of claim 1, wherein L is alkylene, alkenylene, or alkynylene. 11. The method of claim 1, wherein R1 and R2 are independently -H or alkyl. 12. The method of claim 1, wherein v is an integer from 2-5. 13. The method of claim 1, wherein w is an integer from 3-6. 14. The method of claim 1, wherein [D]v is -Leu1-Thr2. 15. The method of claim 1, wherein each E is independently Ser or Ala. 16. The method of claim 5, wherein the cancer is head and neck cancer. 17. The method of claim 5, wherein the cancer is melanoma. 18. The method of claim 5, wherein the cancer is lung cancer. 19. The method of claim 5, wherein the cancer is breast cancer. 20. The method of claim 5, wherein the cancer is glioma. 21. The method of claim 6, wherein the hematological cancer is lymphoma.
Leone-Bay Andrea ; Wang Eric ; Sarubbi Donald J. ; Leipold Harry ; Wang Nai Fang, 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Bond Alan M. (c/o Deakin University Waurn Ponds ; Victoria AUX) Wallace Gordon G. (c/o Deakin University Waurn Ponds ; Victoria AUX) McLachlan Lyle (c/o Commonwealth Ordnance Factory ; West Road Mari, Automated metal detection.
Koerber Steven C. (Encinitas CA) Porter John S. (Leucadia CA) Rivier Jean E. F. (La Jolla CA), Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins.
Bologna William J.,FRX ; Levine Howard L. ; Cartier Philippe,FRX ; de Ziegler Dominique,FRX, Bioadhesive progressive hydration tablets and methods of making and using the same.
Kornreich Wayne D. (San Diego CA) Hernandez Jean-Francois (Qullins CA FRX) Rivier Jean E. F. (La Jolla CA) Rivier Catherine L. (La Jolla CA) Vale ; Jr. Wylie W. (La Jolla CA), CRF antagonists.
Stout Jay (Lincoln NE) Wagner Fred W. (Walton NE) Coolidge Thomas R. (Falls Village CT) Holmquist Bart (Waltham MA), Chemical method for selective modification of the N- and/or C-terminal amino acid a
상세보기
Kalvelage John D. (Lynchburg VA), Child resistant package assembly for dispensing pharmaceutical medications.
Bowers Cyril Y. (New Orleans LA) Momany Frank A. (Concord MA) Chang Ching H. (Kingsport TN) Cody Wayne (Kingsport TN) Hubbs John C. (Gray TN) Foster Charles H. (Kingsport TN), Combinations having synergistic growth hormone releasing activity and methods for use thereof.
Leone-Bay Andrea (Ridgefield CT) Paton Duncan R. (Purdys NY) Ho Koc-Kan (Mt. Kisco NY) DeMorin Frenel (Spring Valley NY), Compounds and compositions for delivering active agents.
Braisted Andrew C. ; Judice J. Kevin ; McDowell Robert S. ; Phelan J. Christopher ; Starovasnik Melissa A. ; Wells James A., Constrained helical peptides and methods of making same.
Borchardt Ronald T. (Lawrence KS) Siahaan Teruna (Lawrence KS) Gangwar Sanjeev (Lawrence KS) Stella Valentino J. (Lawrence KS) Wang Binghe (Norman OK), Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability.
Barker Peter L. (El Granada CA) Burnier John P. (Pacifica CA) Thorsett Eugene D. (Moss Beach CA), Cyclized peptides and their use as platelet aggregation inhibitors.
Bohme Ekkehard H. (Cincinnati OH) Gerhart Fritz (Kehl Leutesheim DEX) Higgins William (Strasbourg FRX), Derivatives of 2,6-diamino-3-haloheptanedioic acid.
Rivier Jean E. F. (La Jolla CA) Porter John S. (Leucadia CA) Hoeger Carl A. (San Marcos CA) Jiang Guangcheng (La Jolla CA) Rivier Catherine L. (La Jolla CA), GNRH antagonists XIII.
Enright, Frederick M.; Jaynes, Jesse M.; Hansel, William; Koonce, Kenneth L.; McCann, Samuel M.; Yu, Wen H.; Melrose, Patricia A.; Foil, Lane D.; Elzer, Philip H., Genes encoding hormone and lytic peptides.
Hoeger Carl A. (San Marcos CA) Rivier Jean E. F. (La Jolla CA) Theobald Paula G. (Oceanside CA) Porter John S. (Leucadia CA) Rivier Catherine L. (La Jolla CA) Vale ; Jr. Wylie W. (La Jolla CA), GnRH analogs.
Hoeger Carl A. (San Marcos CA) Rivier Jean E. F. (La Jolla CA) Theobald Paula G. (Oceanside CA) Porter John S. (Leucadia CA) Rivier Catherine L. (La Jolla CA) Vale ; Jr. Wylie W. (La Jolla CA), GnRH analogs.
Storck, Pierre-Henri; Schoentjes, Bruno; Piettre, Arnaud Marcel Pierre; Ermert, Philipp; Poncelet, Virginie Sophie; Csoka, Imre Christian Francis, Inhibitors of the interaction between MDM2 and p53.
Lane,David Philip; B철ttger,Volker; B철ttger,Angelika; Picksley,Steven Michael; Hochkeppel,Heinz Kurt; Garcia Echeverria,Carlos; Ch챔ne,Patrick; Furet,Pascal, Inhibitors of the interaction between P53 and MDM2.
Enright, Frederick M.; Jaynes, Jesse M.; Hansel, William; Koonce, Kenneth L.; McCann, Samuel M.; Yu, Wen H.; Melrose, Patricia A.; Foil, Lane D.; Elzer, Philip H., Ligand/lytic peptide compositions and methods of use.
Carvalho Joan (Mountain View CA) Watson Alan D. (Campbell CA) Fellmann Jere D. (Livermore CA) Koo Michael David (Santa Clara CA), Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Gutniak Mark K. (Hasselby Strandvag 26 S-165 65 Hasselby SEX) Coolidge Thomas R. (181 Beebe Hill Rd. Falls Village CT 06031) Recker Robert R. (3309 S. 116th St. Omaha NE 68144) Wagner Fred W. (R.R. 1, Method and treatment composition for decreasing patient time in catabolic state after traumatic injury.
Luzzi Louis A. ; Needham Thomas E. ; Hossein Zia ; Dondeti Polireddy, Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa.
Taylor, Ronald; Nardin, Alessandra; Sutherland, William M.; Sokoloff, Mitchell H.; Chung, Leland, Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies.
Fraser, Graeme L.; Hoveyda, Hamid R.; Peterson, Mark L., Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders.
Leone-Bay Andrea ; Ho Koc-Kan ; Press Jeffery Bruce ; Wang Nai-Fang, Modified amino acids and compositions comprising the same for delivering active agents.
Bartkovitz, David Joseph; Chu, Xin-Jie; Liu, Jin-Jun; Morgan Ross, Tina; Zhang, Zhuming, N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Milstein Sam J. ; Barantsevitch Evgueni ; Leone-Bay Andrea ; Wang Nai Fang ; Sarubbi Donald J. ; Santiago Noemi B, Oral delivery composition comprising supramolecular complex.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Grubbs Robert H. ; Miller Scott J. ; Blackwell Helen E., Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis.
Kim Sun H. (Chestnut Hill MA) Keyes Susan R. (Boston MA) Moreau Sylviane (Upton MA) Dong Zheng X. (Framingham MA) Taylor John (Upton MA), Therapeutic peptide derivatives.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.